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EB Simplex Super®cialis Resulting from a Mutation in the
Type VII Collagen Gene
To the Editor:
Epidermolysis bullosa simplex (EBS) is an inherited blistering
disease characterized by intraepidermal cleavage (Gedde-Dahl and
Anton-Lamprecht, 1990; Fine et al, 1991). A very rare subset of
EBS, termed ``EBS super®cialis'' (EBSS), has been described in two
families by Fine et al (1989). Skin biopsy of these patients shows
clefts of variable size just beneath the level of the stratum corneum,
which can be completely separated from the rest of the epidermis in
some cases. In two of the patients reported, there are also some
clefts in the lower one-third of the epidermis.
Together with this unusual clinical picture, most of the patients
show atrophic scarring, milia, nail dystrophy, and blistering
involving the oral cavity. After the ®rst description of EBSS in
two unrelated families, no other cases have been reported,
emphasizing the rareness of these ®ndings.
Up to now, mutations in the genes KRT5, KRT14, and
PLEC1 have been described underlying different subsets of
EBS. None of them, however, is a good candidate for the
super®cial lesions observed in EBSS. KRT5 and KRT14 are
expressed in basal keratinocytes, whereas mutations in the
PLEC1 gene are associated with EBS together with muscular
dystrophy (Smith et al, 1996). In the absence of a candidate
gene for EBSS, we performed a genome-wide screen in one of
the pedigrees previously described (Fine et al, 1989). The
second family was not included in the study, as only the
proband showed evidence of blister formation, suggesting a
sporadic mutation. Brie¯y, the affected individuals studied here
belong to a ®ve-generation pedigree with an autosomal
dominant pattern of inheritance (Fig 1a). In affected family
members, variably sized clefts were noted just beneath the level
of the stratum corneum in each biopsy specimen (Fine et al,
1989). In some, clefts were subcorneal; in others, lower
intraepidermal. In none of the affected individuals was sub-
lamina densa cleavage noted, nor was any diminution of type
VII collagen staining noted using the anti-type VII antibody LH
7:2 (Fine et al, 1989).
A genome-wide screen was performed using a panel of 324
microsatellite markers, with an average marker spacing of 10 cM and
a semiautomated ¯uorescence-based genotyping system (Aita et al,
1999). Two-point linkage analyses were carried out using the
MLINK program of the FASTLINK suite of programs (Lathrop et al,
1984; Cottingham et al, 1993; Schaffer et al, 1994). A disease allele
frequency of 0.001 and an autosomal dominant mode of inheritance
with complete penetrance were assumed. The marker allele
frequencies were estimated from observed and reconstructed
genotypes of founders within the pedigree. To avoid computation
errors due to observed allele frequencies of 0.0, alleles for all markers
were re-coded using the RECODE program (Weeks, 2000).
Multipoint analyses and reconstruction of pedigrees were carried out
using the SIMWALK program version 2.6 (Sobel and Lange, 1996).
The results of the initial genome-wide scan revealed three
chromosomal regions with a maximum two-point LOD score
greater than 1.4, on chromosomes 3 (Zmax = 1.62), 8 (Zmax =
1.80), and 10 (Zmax = 1.40). Haplotype and multipoint analyses of
additional markers allowed us to exclude the regions on chromo-
somes 8 and 10, and to more decisively establish the linkage to
chromosome 3.
A total of 28 additional markers were used for the ®ne-mapping of
the EBSS locus. Maximum two-point LOD scores of 4.11 and 3.77
at q = 0.0 were obtained for markers D3S2420 and D3S3582,
respectively. Multipoint linkage analysis showed a maximum LOD
score of 5.96 for marker D3S2420 (Fig 1b). Finally, analysis of the
reconstructed haplotypes con®rmed the linkage results and placed
the disease locus within a 2.94 cM region on chromosome 3, ¯anked
by markers D3S3624 and D3S1289 (Fig 1a).
According to the different maps derived from the Human
Genome Project (Human Genome Project Working Draft; National
Center for Biotechnology Information; Ensembl Genome Server;
GeneMap'99), the region ¯anked by markers D3S3624 and
D3S1289 spans approximately 10 Mb of genomic DNA on 3p21.
Coincidentally, the COL7A1 gene, in which mutations are
responsible for DEB (Uitto et al, 1999; Fine et al 2000), lies within
this genetic interval. Type VII collagen is the main constituent of the
anchoring ®brils and at the microscopic level, DEB is characterized
by skin cleavage beneath the lamina densa. The morphologic defect
is a reduced number or complete absence of the anchoring ®brils, in
the dominant and recessive forms of DEB, respectively (Tidman and
Eady, 1985). In DEB skin, blisters appear just beneath an intact
lamina densa. In contrast, the family we studied and reported by Fine
et al (1989) showed blister formation just beneath the stratum
corneum. On the basis of the differences in phenotype between
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these two subtypes of EB, the COL7A1 gene was not considered to
be a candidate gene for EBSS. Nevertheless, to unequivocally rule
out this possibility, we performed heteroduplex analysis and direct
sequencing of the coding region.
Quite unexpectedly, we identi®ed a heterozygous transition in
exon 73, 6100G®A, leading to the amino acid change G2034R
(Table I). Exon 73 codes for a 67-amino-acid collagenous
polypeptide sequence preceded by the 39-amino-acid noncollagen-
ous segment (Christiano et al, 1994a). The substitution of a glycine
residue within the collagenous domain of the molecule, character-
ized by the repeating Gly-X-Y sequence, is the major class of
pathogenetic mutations in the dominant forms of DEB (DDEB)
Figure 1. Haplotype and multipoint analysis in the pedigree with EBSS. (a) Pedigree with EBSS and haplotypes for microsatellite markers on
chromosome 3. The disease-associated haplotype is shaded. Asterisks indicate the key recombination events. Non-informative marker is cross-hatched.
Genotypes in parenthesis have been inferred; (b) multipoint LOD scores for family with EBSS. Markers used are listed on the X-axis. The map
positions were computed by SIMWALK 2.6. The order and distance between the markers were deduced from the genetic map at the Center for
Medical Genetics, Marsh®eld Medical Research Foundation (Broman et al, 1998).
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(Christiano et al, 1994b, 1995; Burgeson et al, 1995). Moreover,
mutations involving the glycine residue at position 2034 have been
previously reported (Kon et al, 1997; Hammami-Hauasli et al, 1998;
Rouan et al, 1998; Mecklenbeck et al, 1999) (Table I). The very
same amino acid substitution has been described in three families
with different forms of DDEB: the ``Cockayne-Touraine'' variant of
DDEB (Kon et al, 1997), DDEB ``generalisata'' (Hammami-Hauasli
et al, 1998; Mecklenbeck et al, 1999), and an unspeci®ed subtype of
DEB (Mecklenbeck et al, 1999). In addition, a different amino acid
substitution affecting the same residue, G2034W, has also been
reported. Rouan et al (1998) identi®ed this second amino acid
change in a family with a mild form of DDEB, mainly involving the
hands, feet, and mouth. In another study, Mecklenbeck et al (1999)
described the same mutation, G2034W, in two families with the so-
called DDEB ``localisata'' (Table I). In these families, a clear DDEB
phenotype has been reported, and these types of glycine substitution
mutations are the most prevalent in DDEB.
In light of our results, we believe that the clinical phenotype in
the EBSS kindred studied here actually represents a case of DDEB,
rather than a unique subset of EBS. The molecular data suggest that
the subcorneal cleavage observed in different members of this
kindred would likely not be pathogenic or contribute to the disease
process. As the proband from the second family reported in the
original work (Fine et al, 1989) was not available for this study,
these ®ndings do not fully exclude the possibility that rare forms of
EBS having super®cial skin cleavage may also exist. Although it is
true that the family studied here does indeed have several clinical
®ndings that are commonly associated with DEB, data from the
National EB Registry have also shown that at least 10%±25% of all
EBS patients have one or more of these ``dystrophic'' features as
well, making the diagnosis based on clinical phenotypes sometimes
imprecise. Genetic studies such as the one presented here become
an invaluable tool to clarify the true molecular basis of a disease like
EBSS, where the clinical features cannot be used to unequivocally
classify a particular phenotype. Collectively, these ®ndings allow us
to reclassify a previously uncharacterized form of EB as another
clinical variant of DDEB.
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Table I. Mutations involving residue G2034 in the
COL7A1 gene
Mutation Type of EB Inheritance Reference
G2034R EBSS AD This study
DEB-CTa AD Kon et al (1997)
DEB-generalisata AD Hammami-Hauasli et al (1998);
Mecklenbeck et al (1999)
DEBb AD Mecklenbeck et al (1999)
G2034W DEB-mild AD Rouan et al (1998)
DEB-localisata AD Mecklenbeck et al (1999)
DEB-localisata AD Mecklenbeck et al (1999)
aDDEB-CT: Cockayne-Touraine variant of DDEB.
bThe subtype of EB has not been speci®ed.
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